Research Nester released a report titled “Non-Alcoholic Steatohepatitis (NASH) Therapeutics & Diagnostics Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics market in terms of market segmentation by therapeutics, by diagnostics and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
Non-alcoholic steatohepatitis is a form of fatty liver disease caused by excessive accumulation of fat in the liver. This disease occurs among people who consume little or no alcohol. The market for non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics is anticipated to grow by a significantly high CAGR during the forecast period, i.e., 2019-2027. The market is segmented by therapeutics, by diagnostics and by region, out of which, the therapeutics segment is further segmented into ocaliva, elafibranor, cenicriviroc, selonsertib and others. On the basis of this, the elafibranor segment is predicted to observe a high growth as a result of better efficacy of this drug in serious cases of NASH.
On the basis of regional analysis, the non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is estimated to hold the largest share in the market on account of growing technical advancements in the region which can be attributed to the presence of leading market players. The rising prevalence of obesity and diabetes in the United States and Canada further contributes towards the market growth.
Advances in the Medical Sector to Drive the NASH Therapeutics and Diagnostics Market Growth
The increasing research in this field which results in the development of highly effective and safe drugs and diagnostic techniques is anticipated to be a major factor responsible for the market growth over the forecast period. New innovations in the diagnostic techniques for non-alcoholic steatohepatitis further boost the growth of this market. However, the strict regulatory policies by the government and time-consuming process of clinical trials for drugs are estimated to hamper the market growth in the upcoming years.
This report also provides the existing competitive scenario of some of the key players of the global non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics market which includes company profiling of Siemens Healthcare GmbH (ETR: SHL), Celerion, ZyVersa Therapeutics, Inc., Cisbio, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), BioPredictive, Echosens, Genfit (EPA: GNFT), Enterome and NGM Biopharmaceuticals. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.